Merck & Co., Inc. holds a concentrated book of 13 stocks worth $526.4M as of Q2 2026 (disclosed Aug 7, 2026, a ~38-day 13F lag). This quarter they opened Entrada Therapeutics Inc. Their largest long position is Personalis Inc at 36% of the equity book.
Top-heavy: concentrated book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
100% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Other tracked managers holding the same core names as Merck & Co., Inc.
| Manager / fund | Shared names | Their $ in those |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | 12 / 13 | $1.6B |
| GEODE CAPITAL MANAGEMENT, LLC | 12 / 13 | $1.0B |
| MORGAN STANLEY | 12 / 13 | $471.1M |
| UBS Group AG | 12 / 13 | $335.7M |
| VANGUARD FIDUCIARY TRUST CO | 12 / 13 | $159.4M |
| FMR LLC | 11 / 13 | $3.6B |
| STATE STREET CORP | 11 / 13 | $1.6B |
| Vanguard Global Advisers, LLC | 11 / 13 | $41.4M |
Ranked by how many of Merck & Co., Inc.'s top 13 disclosed names each fund also holds: a cross-fund conviction signal from the latest 13F of every tracked manager.
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Personalis Inc COM | $188.2M | 14.04M | 35.8% | —Held | |
| 2 | Moderna Inc COM | $161.6M | 2.31M | 30.7% | —Held | |
| 3 | Kymera Therapeutics Inc COM | $88.5M | 772.2K | 16.8% | —Held | |
| 4 | Aktis Oncology Inc COM | $30.7M | 952.8K | 5.8% | —Held | |
| 5 | Eikon Therapeutics Inc COM | $21.7M | 1.67M | 4.1% | —Held | |
| 6 | Entrada Therapeutics Inc COM | $12.8M | 1.74M | 2.4% | ▲New New position | |
| 7 | Sutro Biopharma Inc COM | $9.0M | 272.4K | 1.7% | ▲New New position | |
| 8 | Alector Inc COM | $7.1M | 3.55M | 1.4% | —Held | |
| 9 | Evaxion Biotech A/s SPONSORED ADS | $3.8M | 1.21M | 0.7% | ▲New New position | |
| 10 | Viridian Therapeutics Inc COM | $1.7M | 93.4K | 0.3% | —Held | |
| 11 | Xilio Therapeutics Inc COM | $1.0M | 106.0K | 0.2% | —Held | |
| 12 | Tuhura Biosciences Inc COM | $46K | 19.4K | 0.0% | —Held | |
| 13 | Neuphoria Therapeutics Inc COM | $44K | 10.0K | 0.0% | —Held |
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/310158/holdings"
Use Arkolith to show Merck & Co., Inc.'s latest holdings, largest changes, and filing provenance.
As-of date vs the date the SEC received each filing
Holdings from SEC EDGAR 13F-HR filings, updated quarterly, filed up to 45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. Price-derived performance is withheld until the price-source policy and freshness gate are green.